Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
Symbol LATS2 contributors: mct/npt/pgu - updated : 29-10-2015
HGNC name LATS, large tumor suppressor, homolog 2 (Drosophila)
HGNC id 6515
  • N-terminal non-kinase regions are distinct except for LATS conserved domains 1 and 2 (LCD1 and LCD2), which may be important for LATS1/2-specific functions
  • a PAPA repeat with seven copies of the dipeptide proline-alanine, may be involved in protein-protein interactions
  • a kinase domain with presence, also in DMPK, of two negative pockets in the peptide binding groove provides an explanation for the substrate preference
  • a C-terminal serine/threonine kinase domain
    interspecies homolog to Drosophila LATS large tumor suppressor 2
    homolog to Drosophila loss of the lats/warts
    ortholog to murine Lats2
    homolog to C.elegans T20F10.1
    intraspecies homolog to CDC42BP (myotonic DMPK-like)
  • LATS tumor suppressor family
  • Dbf2 kinase family
  • CATEGORY enzyme , tumor suppressor , receptor membrane serine/threonine
    SUBCELLULAR LOCALIZATION     plasma membrane,junction,tight
  • cytoplasmic during interphase, while it becomes localized to the mitotic apparatus during mitosis
  • co-localizing with AURKA at the centrosomes during the cell cycle
  • LATS2, AMOTL2, and YAP1 all localize to tight junctions, raising the possibility that clustering of Hippo pathway components at tight junctions might function to trigger LATS2 activation and growth inhibition in response to increased cell density
  • basic FUNCTION
  • playing a role in suppressing tumor development and regulating cell proliferation
  • functioning as a modulator of AR by inhibiting androgen-regulated gene expression
  • may play a role in AR-mediated transcription and contribute to the development of prostate cancer
  • implicated in regulation of the cell cycle and apoptosis
  • affects both growth and death of cardiac myocytes, but it primarily regulates the size of the heart and acts as an endogenous negative regulator of cardiac hypertrophy
  • may potentially involve in Hippo pathway regulating the fat reduction by inhibiting adipocyte differentiation and growth
  • coordinate the cell cycle, cell proliferation, and cell death, promotes the stabilization of TP53 by inactivating MDM2
  • functions as part of the Hippo pathway to promote contact inhibition of growth and tumor suppression by phosphorylating and inhibiting the transcriptional co-activator YAP1
  • Aurora A-LATS1/2-Aurora B axis might be a novel pathway that regulates accurate mitotic progression by ensuring the proper mitotic localization of LATS2
  • acts as a positive modulator of SNAI1 protein level and potentiates its EMT activity
  • CELLULAR PROCESS cell life, cell death/apoptosis
  • Aurora A-LATS1/2-Aurora B axis might be a novel pathway that regulates accurate mitotic progression
  • a component
  • component of the Hippo tumor-suppressive signaling pathway
  • WWC1-Aurora-LATS2 protein complexes form a novel axis that regulates precise mitosis
    small molecule nucleotide,
  • ATP
  • protein
  • phosphorylation target of Aurora-A kinase (AURKA)(and this phosphorylation plays a role of the centrosomal localization of LATS2)
  • AR-interacting protein
  • LATS1 and LATS2 are novel HSP90AA1 clients and HSP90AA1 inhibitors can disrupt the LATS tumor suppressor pathway in cancer cells
  • AMOT activate LATS2 through a novel conserved domain that binds and activates LATS2
  • binding between WWC1 and LATS2 requires the N-terminal 86 AAs of WWC1 and the PPPY motif and AAs 667788 in LATS2
  • interacting with FOXP3 (LATS2 induction required binding of FOXP3 to a specific sequence in the LATS2 promoter, and this interaction contributed to FOXP3-mediated growth inhibition of tumor cells)
  • LATS2 kinase is a novel regulator of SNAI1 protein level, subcellular localization, and thus, activity
  • LATS2 modulates ESR1-regulated gene transcription, through direct and/or indirect interactions with ESR1
  • involved in phosphorylation of AMOT130, which is a key feature that enables it to inhibit YAP1-dependent signaling and cell growth
  • AMOT is a direct substrate of LATS1/LATS2 mediating functions of the Hippo pathway in endothelial cell migration and angiogenesis
  • LATS1, LATS2 can synergize with F-actin perturbations by phosphorylating free AMOT130 to keep it from associating with F-actin
  • LATS1 and LATS2 phosphorylate CDC26 to modulate assembly of the tetratricopeptide repeat subcomplex of APC/C
  • cell & other
    activated by activated by the MST2 kinase
    repressed by tristetraprolin (TTP) (overexpression of TTP reduced the expression level of LATS2)
    Phosphorylated by AURKA (Aurora A was demonstrated to phosphorylate LATSs2 on serine 380 (S380) during mitosis)
    corresponding disease(s)
    Other morbid association(s)
    TypeGene ModificationChromosome rearrangementProtein expressionProtein Function
    tumoral     --low  
    in prostate cancer
    tumoral     --low  
    by promoter hypermethylation-mediated in astrocytoma
    tumoral       loss of function
    is one of the key mechanisms for constitutive activation of YAP1, which induces deregulation of malignant mesothelioma cell proliferation
    tumoral     --low  
    of LATS1 and LATS2 by promoter hypermethylation is associated with a biologically aggressive phenotype in breast cancer
    tumoral     --low  
    in breast and prostate cancer and acts as an important tumor suppressor relay between the FOXP3 and HIPPO pathways which are widely implicated in cancer (
    constitutional     --over  
    reduced left ventricular systolic and diastolic function without affecting baseline levels of myocardial apoptosis
    Variant & Polymorphism
    Candidate gene
    Therapy target
    useful target for astrocytoma therapy